Precigen UltraCAR-T Technology Flexes its Muscles at ASH Meeting

Published on :

At the American Society of Hematology meeting earlier this month, Precigen presented positive interim data from an ongoing Phase 1/2b clinical study of PRGN-3006 UltraCAR-T in patients who have been diagnosed with relapsed or refractory (r/r) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). The interim study data showed what the trial investigators are calling “excellent, dose-dependent expansion.”

CRB Life Sciences Report Highlights Looming Changes in Cell Therapy Space

Pink and purple DNA strands with "Horizons" text
Published on :

The Horizon report is based on survey responses from more than 500 industry leaders who provide insight into all corners of the industry. The investigation of cell and gene therapies is proving to be a disruptive space that is reshaping biopharma business models. When cell therapies first went into human testing, Walters said the big question on the minds of the scientists was, “will it work?”

BlueSphere Bio Aims for Next-Level Personalized Cancer Cell Therapy

Headshot of David Apelian
Published on :

Chimeric Antigen Receptor T cell (CAR-T) therapies, such as those developed by Kite Pharma, have revolutionized the approach to treating hematological cancers, but the therapies have limitations due to toxicity concerns. Pennsylvania-based BlueSphere Bio believes its approach through the use of TCR-T cell therapies will provide a more precise treatment option for patients.

CaroElise Ataku: Driven by a Shared Purpose in Producing Personalized Cell Therapies to Fight Cancer

Published on :

Kite specializes in personalized chimeric antigen receptor (CAR) T-cell therapies for the treatment of certain blood cancers and CTSs play a critical role in the process that develops those therapies. Each day, a CTS receives batches of patient cells in their own hands, with each batch representing a new patient. Most of these patients have already exhausted other treatment options. The patient focus and the company’s mission to get these therapies to the people who need them most is the foundation of employees’ day-to-day work.

BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD

Published on :

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany. The facility will support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T Cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms as well as the newly acquired individualized neoantigen TCR program.

Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies

Published on :

Arcellx, a privately held clinical- stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022. In addition, the funding will support initiation of clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from Arcellx’s uniquely controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively.